Literature DB >> 18508446

Soluble NKG2D ligands: prevalence, release, and functional impact.

Helmut Rainer Salih1, Stefan Holdenrieder, Alexander Steinle.   

Abstract

Natural Killer (NK) cells are capable to recognize and eliminate malignant cells. Anti-tumor responses of NK cells are promoted by the tumor-associated expression of cell stress-inducible ligands of the activating NK receptor NKG2D. Current evidence suggests that established tumors subvert NKG2D-mediated tumor immunosurveillance by releasing NKG2D ligands (NKG2DL). Release of NKG2DL has been observed in a broad variety of human tumor entities and is thought to interfere with NKG2D-mediated tumor immunity in several ways. Further, levels of soluble NKG2DL (sNKG2DL) were also found to be elevated under various non-malignant conditions, although the functional implications remain largely unclear. Here we review and discuss the available data on the prevalence, release, functional impact, and potential clinical value of sNKG2DL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18508446     DOI: 10.2741/2939

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  50 in total

1.  NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease.

Authors:  Nobuyoshi Hanaoka; Bana Jabri; Zhenpeng Dai; Cezary Ciszewski; Anne M Stevens; Cassian Yee; Hideki Nakakuma; Thomas Spies; Veronika Groh
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

2.  Acquisition of activation receptor ligand by trogocytosis renders NK cells hyporesponsive.

Authors:  Cathrine A Miner; Tusar K Giri; Claire E Meyer; Mark Shabsovich; Sandeep K Tripathy
Journal:  J Immunol       Date:  2015-01-12       Impact factor: 5.422

Review 3.  Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells.

Authors:  Suresh Bugide; Radoslav Janostiak; Narendra Wajapeyee
Journal:  Trends Cancer       Date:  2018-07-03

4.  Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors.

Authors:  Shengjun Lu; Jinyu Zhang; Dai Liu; Guangfu Li; Kevin F Staveley-O'Carroll; Zihai Li; Jennifer D Wu
Journal:  Clin Cancer Res       Date:  2015-06-23       Impact factor: 12.531

5.  Soluble MICA is elevated in pancreatic cancer: Results from a population based case-control study.

Authors:  Guillaume Onyeaghala; Heather H Nelson; Bharat Thyagarajan; Amy M Linabery; Angela Panoskaltsis-Mortari; Myron Gross; Kristin E Anderson; Anna E Prizment
Journal:  Mol Carcinog       Date:  2017-05-24       Impact factor: 4.784

Review 6.  NK cells and cancer: you can teach innate cells new tricks.

Authors:  Maelig G Morvan; Lewis L Lanier
Journal:  Nat Rev Cancer       Date:  2016-01       Impact factor: 60.716

7.  NKG2D Ligands in Cancer Immunotherapy: Target or Not?

Authors:  Jennifer Wu
Journal:  Austin J Clin Immunol       Date:  2014-01-06

8.  HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing.

Authors:  Jonathan Richard; Sardar Sindhu; Tram N Q Pham; Jean-Philippe Belzile; Eric A Cohen
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

Review 9.  Natural killer cell receptors and their ligands in liver diseases.

Authors:  Satoshi Yamagiwa; Hiroteru Kamimura; Takafumi Ichida
Journal:  Med Mol Morphol       Date:  2009-03-18       Impact factor: 2.309

10.  Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells.

Authors:  Yan Chen; Bei Chen; Ti Yang; Weiming Xiao; Li Qian; Yanbing Ding; Mingchun Ji; Xiaoqun Ge; Weijuan Gong
Journal:  Cell Mol Immunol       Date:  2015-09-14       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.